Table 4.
Model name | Evaluation method | Q (%) | SE (%) | SP (%) | Reference |
---|---|---|---|---|---|
MC4PCa | 10-fold CVe | 66.5 | 61.4 | 70.9 | 14 |
MDL-QSARb | 10-fold CV | 69.2 | 62.8 | 74.8 | 14 |
lazar | LOOCVf | 66.9 | 59.9 | 73.4 | 15 |
Naïve Bayesian | 5-fold CV | 68 | 57 | 79 | 16 |
CP ANN MDLc | 5-fold CVg | 66 | — | — | 12 |
CP ANN Dragon (VEGA CAESAR)c | 5-fold CV | 62 | — | — | 12 |
VEGA IRFMN/Antares | 5-fold CV | 66.0 | 83.1 | 48.3 | 29 |
VEGA IRFMN/ISSCAN-CGXd | 5-fold CV | 72.7 | 76.5 | 61.8 | 29 |
aThe coverage of this model was 96%. bThe coverage of this model was 97%. cThis study did not provide the SE and SP of the models. dThis model was trained using carcinogenesis data from both rats and mice. eTen-fold cross-validation. fLeave-one-out cross-validation. gFive-fold cross-validation.